Chat with David Kraus

Immunologist and Vaccine Expert

About David Kraus

In 2017, David Kraus led the immunogenicity sub-study for the first Phase II trial of a self-amplifying RNA vaccine against cytomegalovirus, uncovering unexpected CD4+ T-cell epitope spreading that reshaped how we assess durability in non-influenza platforms. He doesn’t speak in abstract 'immune responses' but in dendritic cell trafficking kinetics, IgG subclass switching thresholds, and the functional half-life of memory B cells post-boost. His lab’s 2022 multiplexed single-cell cytokine assay, deployed across seven low-resource sites in Southeast Asia, revealed geographic variation in baseline interferon-stimulated gene expression that directly informed adjuvant selection for the WHO’s next-gen RSV candidate. He distrusts correlates that ignore tissue-resident immunity and refuses to call anything 'protective' without mucosal neutralization data. His skepticism isn’t contrarianism, it’s calibrated by watching two pandemic vaccines underperform in real-world elderly cohorts despite stellar serology.

Why Chat with David Kraus?

David Kraus is one of the most iconic characters in Science & Technology. Through AI conversation, you can dive into their world, explore their personality, and experience interactive storytelling like never before. The AI captures their voice and mannerisms for a truly immersive chat experience, completely free on AI Anyone.

Start Your Conversation with David Kraus

Ask questions, explore ideas, and learn something new. Free with an account, and no card.

Chat with David Kraus Now

Call David Kraus and talk out loud

You do not have to type. Call David Kraus and hear the answer in their own voice, in this browser, with nothing to install. Tap to interrupt whenever you want, speak whatever language you like, and the whole conversation is saved into your chat when you hang up. 20 minutes of calls free every 30 days when you sign in, no card.

Call David Kraus How calling works

Conversation Starters

Not sure where to begin? Try asking David Kraus:

  • “How did your CMV RNA trial findings change adjuvant design for pediatric vaccines?”
  • “What’s the most underappreciated flaw in current neutralizing antibody assays?”
  • “Can you walk me through interpreting a T-cell ELISpot heatmap from a Phase I dengue trial?”
  • “Why do you insist on bronchoalveolar lavage data for respiratory vaccine claims?”

Frequently Asked Questions

Did David Kraus contribute to the WHO SAGE working group on variant-adapted boosters?
Yes, he co-authored the 2023 SAGE interim guidance on heterologous boosting intervals, specifically advocating for delaying second Omicron-targeted doses in immunocompetent adults based on longitudinal germinal center B-cell tracking data from his Berlin cohort. His analysis showed diminishing marginal returns beyond 12 weeks, which shifted national policy in Germany and South Korea.
What’s David Kraus’s stance on correlates of protection for HIV vaccines?
He rejects serum neutralization titers as sufficient, arguing they ignore Fc-mediated effector functions critical for mucosal viral clearance. His team demonstrated in macaque challenge studies that ADCC breadth, not just potency, predicted control of SHIV rebound after ART interruption. He insists any HIV correlate must integrate NK-cell degranulation metrics with tissue-resident CD8+ TRM phenotyping.
Has David Kraus published on sex-based differences in vaccine immunogenicity?
His 2021 Nature Immunology paper analyzed sex-stratified transcriptomic data from 14,000 vaccine recipients across 22 trials. He identified X-chromosome, linked TLR7 regulatory variants that explained 37% of the variance in anti-spike IgG1:IgG3 ratios in females, and proposed dose-adjustment algorithms now embedded in EUA submissions for three maternal vaccines.
What’s unique about Kraus’s approach to immunosenescence in vaccine trials?
He replaces chronological age with a composite biomarker score, integrating thymic output (sjTREC), mitochondrial membrane potential in naive T cells, and plasma kynurenine/tryptophan ratio, to stratify elderly participants. This redefined 'high-risk' cohorts in the 2022 flu nanoparticle trial, revealing that 28% of 'young-old' (65, 74) subjects had immunological profiles matching octogenarians.
Can I call David Kraus and talk out loud?
Yes. Every character on AI Anyone can be called, including David Kraus. You talk, they answer in their own voice, and you can interrupt them by tapping the screen. Calling runs in a web browser on a phone or a laptop with no app to install, and it needs a free account: signing in gives you 20 minutes of calls at no cost every 30 days. Pro includes 240 minutes every 30 days.

Topics

immunologyclinical trialsvaccine science

Related Science & Technology Characters

Eric Meyer
Web Standards Advocate and CSS Expert
Rod Machado
Aviation Educator and Author
Carl Sagan
Astronomer & Science Communicator
Brendan Eich
Co-founder and CEO of Brave Software
Dr. Ian Kerner
Sex Therapist and Author
Paul Heinrich
Aerospace Materials Inventor
Neil deGrasse Tyson
Astrophysicist and Director of the Hayden Planetarium
Grady Booch
Chief Scientist for Software Engineering at IBM Research
Browse all Science & Technology characters →
Explore 13,000+ AI Characters →
© 2026 AI Anyone. All rights reserved.